United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, TD Cowen Analyst Says

United Therapeutics (NASDAQ:UTHR) had its target price boosted by equities research analysts at TD Cowen from $575.00 to $660.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price target would suggest a potential upside of 11.30% from the company’s current price.

Several other analysts have also commented on the stock. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Wells Fargo & Company lifted their price objective on United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a research report on Monday, March 23rd. HC Wainwright upped their target price on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Stock Up 0.8%

Shares of NASDAQ:UTHR opened at $592.98 on Monday. The company has a market cap of $25.99 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 2.12 and a beta of 0.84. The firm’s 50-day simple moving average is $500.92 and its 200-day simple moving average is $476.29. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $6.19 earnings per share. On average, research analysts forecast that United Therapeutics will post 24.48 EPS for the current year.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $471.91, for a total value of $10,617,975.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 333,820 shares of company stock valued at $165,495,478. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter valued at approximately $317,617,000. Norges Bank acquired a new position in United Therapeutics during the fourth quarter valued at approximately $293,418,000. Invesco Ltd. grew its stake in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the period. Finally, Avoro Capital Advisors LLC grew its stake in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 Phase 3 success — The pivotal TETON‑1 study met its primary endpoint, showing a clinically meaningful FVC improvement (Hodges‑Lehmann estimate ~130.1 mL vs placebo at 52 weeks), supporting Tyvaso’s potential expansion into IPF and a likely regulatory path. BusinessWire: TETON‑1 Results
• Positive Sentiment: Wall Street upgrades and target lifts — Multiple firms raised price targets (TD Cowen, HC Wainwright, BofA, TD Cowen to ~$660 among others), reflecting materially higher revenue/market‑expansion assumptions if Tyvaso wins an IPF label. TickerReport: HC Wainwright Raise
• Positive Sentiment: Buyback / ASR and ralinepag momentum — Recent company buyback authorizations (including accelerated share repurchase activity) and positive Phase 3 ralinepag data (PAH) add to near‑term shareholder‑return dynamics and reduce share count risk. QuiverQuant: Buyback & Ralinepag
• Neutral Sentiment: Heavy call‑option activity and volume — Unusually large call buying and above‑average equity volume indicate speculative positioning and short covering; this can amplify moves short term but is not a fundamental read‑through by itself.
• Neutral Sentiment: Mixed analyst stances — Some firms raised targets but kept neutral/equal‑weight ratings (e.g., Wells Fargo, BofA), signaling differing views on how much IPF uptake and pricing convert to durable earnings. 24/7 Wall St.: Dual Target Hikes
• Negative Sentiment: Valuation and execution risk cautions — Some analysts note that strong trial momentum is partially offset by high valuation and execution/regulatory risk (commercial rollout, payer uptake), which could limit further multiple expansion. TipRanks: Balanced View
• Negative Sentiment: Large insider selling flagged — Public filings compiled by data providers show extensive insider sales over recent months; investors often view concentrated insider selling as a negative signal to monitor. QuiverQuant: Insider Activity
• Negative Sentiment: Questions about sustainability of the move — Some market commentaries (and earnings‑estimate trends) warn the post‑trial pop may not sustain unless follow‑on commercialization, label, and payer access dynamics become clearer. Zacks: Will Strength Last?

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.